Richard J. Jones, Ph.D.
Department of Lymphoma and Myeloma, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Lymphoma/Myeloma - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2012 | MD Anderson Cancer Center, Houston, TX, USA, Instructor, Experimental Cancer Therapeutics |
| 2010 | MD Anderson Cancer Center, Houston, TX, USA, Post-Doctoral Fellowship, Experimental Cancer Therapeutics |
| 2007 | UNC-Chapel Hill, Chapel Hill, NC, USA, Post-Doctoral Fellowship, Experimental Cancer Therapeutics |
| 2006 | UNC-Chapel Hill, Chapel Hill, NC, USA, Post-Doctoral Fellowship, Virology/Gene Therapy |
| 2003 | University of Birmingham, UK, Birmingham, GBR, PHD, Cancer Studies |
| 2003 | University of Birmingham, Birmingham, GBR, Post-Doctoral Fellowship, Virology/Gene Therapy |
| 1999 | University of Wolverhampton, Wolverhampton, GBR, BS, Sandwich, Biomedical Science |
| 1995 | Joseph Chamberlain Sixth Form College, Birmingham, GBR, GCE, Biology, Chemistry, Psychology |
Postgraduate Training
| 1999-2003 | Ph.D, Cancer Research United Kingdom (CRUK) Institute for Cancer Studies, University of Birmingham, Birmingham |
Experience & Service
Academic Appointments
Research Instructor, Department of Lymphoma/Myeloma - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - Present
Post-Doctoral Research Fellow, Department of Lymphoma/Myeloma - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2010
Post-Doctoral Research Fellow, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 2004 - 2007
Other Appointments/Responsibilities
PhD Student, (Laboratory of Professor Lawrence Young), Institute for Cancer Studies, Birmingham University, Birmingham, 1999 - 2033
Research Assistant, Institute for Cancer Studies, Birmingham University, Birmingham, 1997 - 1998
Honors & Awards
| 2011 | Division Of Cancer Medicine Research Awards 2012, MD Anderson Cancer Center |
| 2010 | Fellowship Grant, Lymphoma Research Foundation |
| 2007 | Young Investigator Award, American Association for Cancer Research (AACR) |
| 2002 | Young Scientist Communicators Award, Royal Institute, London, United Kingdom |
| 1999 | Medical Research Council Scholarship, University of Birmingham, United Kingdom |
Selected Publications
Peer-Reviewed Articles
- Shirazi F, Jones RJ, Singh RK, Zou J, Kuiatse I, Berkova Z, Wang H, Lee HC, Hong S, Dick L, Chattopadhyay N, Orlowski RZ. Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma. Proc Natl Acad Sci U S A 117(33):20004-20014, 2020. e-Pub 2020. PMID: 32747568.
- Sheller-Miller S, Radnaa E, Arita Y, Getahun D, Jones RJ, Peltier MR, Menon R. Environmental pollutant induced cellular injury is reflected in exosomes from placental explants. Placenta 89:42-49, 2020. e-Pub 2019. PMID: 31675489.
- Zhuang J, Shirazi F, Singh RK, Kuiatse I, Wang H, Lee HC, Berkova Z, Berger A, Hyer M, Chattopadhyay N, Syed S, Shi JQ, Yu J, Shinde V, Tirrell S, Jones RJ, Wang Z, Davis RE, Orlowski RZ. Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. Blood 133(14):1572-1584, 2019. e-Pub 2019. PMID: 30737236.
- Purushothaman A, Bandari SK, Chandrashekar DS, Jones RJ, Lee HC, Weber DM, Orlowski RZ. Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes. Oncotarget 8(43):73723-73732, 2017. e-Pub 2017. PMID: 29088739.
- Lee HC, Wang H, Baladandayuthapani V, Lin H, He J, Jones RJ, Kuiatse I, Gu D, Wang Z, Ma W, Lim J, O'Brien S, Keats J, Yang J, Davis RE, Orlowski RZ. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma. Br J Haematol 177(1):80-94, 2017. PMID: 28369725.
- Jones RJ, Iempridee T, Wang X, Lee HC, Mertz JE, Kenney SC, Lin HC, Baladandayuthapani V, Dawson CW, Shah JJ, Weber DM, Orlowski RZ. Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle Through Phosphoinositide 3-kinase Signaling and Ikaros Expression. Clin Cancer Res 22(19):4901-4912, 2016. e-Pub 2016. PMID: 27297582.
- Ma SD, Xu X, Jones R, Delecluse HJ, Zumwalde NA, Sharma A, Gumperz JE, Kenney SC. PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model. PLoS Pathog 12(5):e1005642, 2016. e-Pub 2016. PMID: 27186886.
- Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang XD, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ. Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia. Clin Cancer Res 21(11):2538-45, 2015. e-Pub 2015. PMID: 25748087.
- Wen J, Tao W, Kuiatse I, Lin P, Feng Y, Jones RJ, Orlowski RZ, Zu Y. Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. Int J Cancer 136(5):991-1002, 2015. e-Pub 2014. PMID: 25042852.
- Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y, Grant S. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood 124(17):2687-97, 2014. e-Pub 2014. PMID: 25208888.
- Chen S, Zhou L, Zhang Y, Leng Y, Pei XY, Lin H, Jones R, Orlowski RZ, Dai Y, Grant S. Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik. Mol Cell Biol 34(18):3435-49, 2014. e-Pub 2014. PMID: 25002530.
- Gu D, Wang S, Kuiatse I, Wang H, He J, Dai Y, Jones RJ, Bjorklund CC, Yang J, Grant S, Orlowski RZ. Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. PLoS One 9(9):e103015, 2014. e-Pub 2014. PMID: 25181509.
- Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn DJ, Orlowski RZ. Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase is Mediated by Point Mutations of p53, but can be Overcome with the p53 Targeting Agent RITA. Mol Cancer Ther 11(10):2243-53, 2012. e-Pub 2012. PMID: 22933706.
- Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZ. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood 118(15):4140-9, 2011. e-Pub 2011. PMID: 21844567.
- Jones RJ, Rakesh S, Fayad LE, Romaguera JE, Wang M, Yang D, Orlowski RZ. HDM-2 Inhibition Suppresses Expression of Ribonucleotide Reductase Subunit M2, and Synergistically Enhances Gemcitabine-induced Cytotoxicity in Mantle Cell Lymphoma. Blood 118:4140-4149, 2011.
- Ryan JL, Jones RJ, Kenney SC, Rivenbark AG, Tang W, Knight ER, Coleman WB, Gulley ML. Epstein-Barr virus-specific methylation of human genes in gastric cancer cells. Infect Agent Cancer 5:27, 2010. e-Pub 2010. PMID: 21194482.
- Ryan JL, Jones RJ, Elmore SH, Kenney SC, Miller G, Schroeder JC, Gulley ML. Epstein-Barr virus WZhet DNA can induce lytic replication in epithelial cells in vitro, although WZhet is not detectable in many human tissues in vivo. Intervirology 52(1):8-16, 2009. e-Pub 2009. PMID: 19349713.
- Jones RJ, Chen Q, Voorhees PM, Young KH, Bruey-Sedano N, Yang D, Orlowski RZ. Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma. Clin Cancer Res 14(17):5416-25, 2008. PMID: 18765533.
- Feng WH, Kraus RJ, Dickerson SJ, Lim HJ, Jones RJ, Yu X, Mertz JE, Kenney SC. ZEB1 and c-Jun levels contribute to the establishment of highly lytic Epstein-Barr virus infection in gastric AGS cells. J Virol 81(18):10113-22, 2007. e-Pub 2007. PMID: 17626078.
- Jones RJ, Seaman WT, Feng WH, Barlow E, Dickerson S, Delecluse HJ, Kenney SC. Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease. Int J Cancer 121(6):1274-81, 2007. PMID: 17520680.
- Jones RJ, Dickerson S, Bhende PM, Delecluse HJ, Kenney SC. Epstein-Barr virus lytic infection induces retinoic acid-responsive genes through induction of a retinol-metabolizing enzyme, DHRS9. J Biol Chem 282(11):8317-24, 2007. e-Pub 2007. PMID: 17244623.
- Jones RJ, Smith LJ, Dawson CW, Haigh T, Blake NW, Young LS. Epstein-Barr virus nuclear antigen 1 (EBNA1) induced cytotoxicity in epithelial cells is associated with EBNA1 degradation and processing. Virology 313(2):663-76, 2003. PMID: 12954232.
- Dawson CW, Dawson J, Jones R, Ward K, Young LS. Functional differences between BHRF1, the Epstein-Barr virus –encoded Bcl - 2 homologue, and Bcl - 2 in human epithelial cells. Journal of Virology 72(11):9016-24, 1998.
- Zhang X, Lee HC, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Singh RK, Lu J, Qian Y, Raina K, Coleman KG, Crews CM, Li B, Wang H, Hailemichael Y, Thomas SK, Wang Z, Davis RE, Orlowski RZ. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia. e-Pub 2018. PMID: 29581547.
- Jones RJ, Gu D, Bjorklund CC, Kuiatse I, Remaley AT, Bashir T, Vreys V, Orlowski RZ. The Novel Anti-cancer Agent JNJ-26854165 Induces Cell Death Through Inhibition of Cholesterol Transport and Degradation of ABCA1. J Pharmacol Exp Ther. e-Pub 2013. PMID: 23820125.
- Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a Role for CD44 and Cell Adhesion in Mediating Resistance to Lenalidomide in Multiple Myeloma: Therapeutic Implications. Leukemia. e-Pub 2013. PMID: 23760401.
- Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma. Blood. e-Pub 2012. PMID: 22932796.
Invited Articles
- Gingras MC, Jones RJ. Exosome targeted therapy, a step in the future. Transl Cancer Res 2017, 2017.
Grant & Contract Support
| Title: | Inhibiting the HDM-2 E3 Ubiquitin E3 ligase as a strategy against Non Hodgkins Lymphoma |
| Funding Source: | Lymphoma Research Foundation |
| Role: | Postdoctoral Fellow |
| Title: | Career Development Award |
| Funding Source: | Department of Defense (DOD) |
| Role: | Principal Investigator |
| Title: | |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Investigations of HDL cholesterol and its transporter ABCA1 in multiple myeloma |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Principal Investigator |
| Title: | Career Development Program |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Research Scholar |
| Title: | Translational Research Program |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Principal Investigator |